Mosanna Therapeutics raises $80M to tackle sleep apnoea with novel nasal spray
Health Tech World covers Mosanna Therapeutics’ impressive $80 million raise to advance the development of a groundbreaking nasal spray treatment for obstructive sleep apnoea. The therapy aims to offer a more convenient and accessible alternative to existing devices like CPAP machines, which many patients find difficult to tolerate.
This funding marks a major milestone for the company and could signal a significant shift in how sleep-related breathing disorders are treated, with wider implications for digital health and respiratory-focused MedTech innovation.
🔗 Read the full article on Health Tech World: Mosanna Therapeutics raises $80M to develop nasal spray for sleep apnoea
Credit for images and content: Health Tech World
____________________________________________________________________________________________________________________________________________________________________________________________________
Cure Talent is a recruitment agency dedicated to the medical technology industry. Whether you are looking for a new role in the medical device sector or you’re an innovative medical device, digital health, or biotech company looking for staff, get in touch with the team today and explore how Cure Talent can help!